Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
84 hedge funds and large institutions have $138M invested in Checkpoint Therapeutics in 2025 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 23 closing their positions.
288% more capital invested
Capital invested by funds: $35.5M → $138M (+$102M)
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
24% more funds holding
Funds holding: 68 → 84 (+16)
18.03% more ownership
Funds ownership: 23.02% → 41.04% (+18%)
19% less call options, than puts
Call options by funds: $1.32M | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$20.2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$12.8M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$11.4M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$10.5M |
| 5 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
+$7.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$14.3M |
| 2 |
Morgan Stanley
New York
|
-$794K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$759K |
| 4 |
Goldman Sachs
New York
|
-$628K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$546K |
CKPT Hedge Fund Activity: Q1 2025 in Review
84 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2025, worth a combined $138M — up 288% from $35.5M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CKPT positions and 23 closed out — a net gain of 16 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $20.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $14.3M sold.
- 84 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2025, up from 68 in Q4 2024.
- Funds reported $138M of Checkpoint Therapeutics stock for Q1 2025, up 288% quarter-over-quarter.
- 39 funds opened new Checkpoint Therapeutics positions in Q1 2025 and 23 closed out, a net change of +16 holders.
- The largest Checkpoint Therapeutics buyer in Q1 2025 was Beryl Capital Management, an estimated $20.2M added.
- The largest Checkpoint Therapeutics seller in Q1 2025 was Armistice Capital, an estimated $14.3M sold.
Based on aggregated 13F filings for Q1 2025.